Abstract
To the Editor: We read with interest the letter by Dr Reuser titled “Inconsistent Reporting About Dosing, Dosing Regimen, and Immunomodulation Therapy in Pompe Disease.”1 In our 2001 article, “Recombinant Human Acid α-Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of a Phase I/II Clinical Trial,”2 we had reported the initial use of recombinant human acid α-glucosidase (rhGAA) in three infantile patients with Pompe disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
